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BSTRACT
 
Background
 
The Ehlers–Danlos syndrome is a her-
itable connective-tissue disorder caused by defects in
fibrillar-collagen metabolism. Mutations in the type V
collagen genes account for up to 50 percent of cases
of classic Ehlers–Danlos syndrome, but many other
cases are unexplained. We investigated whether the
deficiency of the tenascins, extracellular-matrix pro-
teins that are highly expressed in connective tissues,
was associated with the Ehlers–Danlos syndrome.
 
Methods
 
We screened serum samples from 151 pa-
tients with the classic, hypermobility, or vascular types
of the Ehlers–Danlos syndrome; 75 patients with pso-
riasis; 93 patients with rheumatoid arthritis; and 21
healthy persons for the presence of tenascin-X and
tenascin-C by enzyme-linked immunosorbent assay.
We examined the expression of tenascins and type V
collagen in skin by immunohistochemical methods
and sequenced the tenascin-X gene.
 
Results
 
Tenascin-X was present in serum from all
normal subjects, all patients with psoriasis, all patients
with rheumatoid arthritis, and 146 of 151 patients with
the Ehlers–Danlos syndrome. Tenascin-X was absent
from the serum of the five remaining patients with
Ehlers–Danlos syndrome, who were unrelated. Ten-
ascin-X deficiency was confirmed in these patients
by analysis of skin fibroblasts and by immunostaining
of skin. The expression of tenascin-C and type V col-
lagen was normal in these patients. All five of these
patients had hypermobile joints, hyperelastic skin,
and easy bruising, without atrophic scarring. Tenascin-
X mutations were identified in all tenascin-X–defi-
cient patients; one patient had a homozygous tenas-
cin-X gene deletion, one was heterozygous for the
deletion, and three others had homozygous truncat-
ing point mutations, confirming a causative role for
tenascin-X and a recessive pattern of inheritance.
 
Conclusions
 
Tenascin-X deficiency causes a clini-
cally distinct, recessive form of the Ehlers–Danlos
syndrome. This finding indicates that factors other
than the collagens or collagen-processing enzymes
can cause the syndrome and suggests a central role
for tenascin-X in maintaining the integrity of collag-
enous matrix. (N Engl J Med 2001;345:1167-75.)
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HE Ehlers–Danlos syndrome is a genetical-
ly heterogeneous group of heritable connec-
tive-tissue disorders characterized by hyper-
extensible skin, hypermobile joints, and
tissue fragility.
 
1,2
 
 Ultrastructural studies of the skin in
the Ehlers–Danlos syndrome frequently reveal abnor-
mal heterotypic collagen fibrils containing collagen
types I, III, and V, indicating that the syndrome is a
disorder of the collagen fibril.
 
3
 
 This concept is sup-
ported by the identification of mutations in genes en-
coding the fibrillar collagens or collagen-modifying
enzymes in patients with the Ehlers–Danlos syn-
drome.
 
4-12
 
 Thirty to 50 percent of patients with clas-
sic Ehlers–Danlos syndrome have haploinsufficiency
of the gene encoding type V collagen (
 
COL5A1
 
).
 
13,14
 
Thus, although type V collagen mutations are an im-
portant cause of classic Ehlers–Danlos syndrome, oth-
er genes are probably involved in its pathogenesis.
The tenascins are a family of at least three struc-
turally similar extracellular-matrix proteins.
 
15
 
 Two of
them, tenascin-C and tenascin-X, are expressed in the
tissues affected in the Ehlers–Danlos syndrome, in-
cluding skin, tendons, muscle, and blood vessels.
 
16-20
 
This pattern suggests a potential role in the Ehlers–
Danlos syndrome.
Tenascin-X is a large extracellular-matrix protein
that was originally identified because the gene encod-
ing it overlaps 
 
CYP21,
 
 the gene that encodes steroid
21-hydroxylase.
 
21,22
 
 We previously described a patient
with a contiguous-gene syndrome consisting of con-
genital adrenal hyperplasia (due to 21-hydroxylase de-
ficiency) and classic Ehlers–Danlos syndrome (appar-
ently due to deficiency of tenascin-X).
 
23
 
 In that index
patient, tenascin-X protein and messenger RNA were
absent from skin and cultured skin fibroblasts, and a
large deletion encompassing all of 
 
CYP21
 
 and part
of the tenascin-X gene was found on one allele. Al-
though the findings in this patient suggested an es-
sential function for one of the tenascins in vivo,
 
24,25
 
it remained unclear whether Ehlers–Danlos syndrome
due to tenascin-X deficiency is dominant or reces-
T
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sive. Furthermore, it was not known whether isolated
deficiency of tenascin-X without congenital adrenal
hyperplasia occurs, and if so, whether it causes the
Ehlers–Danlos syndrome. Because tenascin-X is a
secreted protein, we identified tenascin-X in normal
serum and then developed protein-based assays to
measure tenascin-X and tenascin-C in serum samples
collected from patients with the Ehlers–Danlos syn-
drome.
 
METHODS
 
Study Population
 
The human-research committees of both participating institu-
tions approved the study protocol, and all patients gave written
informed consent. Serum was obtained from 151 patients with the
Ehlers–Danlos syndrome, who were identified through the Dutch
Ehlers–Danlos syndrome organization. The referring diagnosis was
classic Ehlers–Danlos syndrome in 35 patients, isolated joint hyper-
mobility in 87, and vascular-type Ehlers–Danlos syndrome in 1;
28 patients were unclassified. Serum was also collected from 21
normal persons, 75 patients with psoriasis, and 93 patients with
rheumatoid arthritis. The samples were stored at ¡20°C until used.
Five tenascin-X–deficient persons and their available relatives
were examined by one of us according to the criteria of Beighton et
al. for Ehlers–Danlos syndrome subtypes.
 
2
 
 We used the nine-point
Beighton scale to score joint hypermobility. Patients received a score
of 1 for each fifth finger dorsiflexed more than 90 degrees, 1 for
each thumb apposed to the wrist, 1 for each elbow hyperextended
more than 10 degrees, 1 for each knee hyperextended more than
10 degrees, and 1 if the palms could be placed on the floor with
the knees locked; the maximal score was 9 points. A score of 5 or
more defines hypermobility. Skin hyperelasticity was scored on a
three-point scale (0, 1, or 2); higher scores indicate greater elastic-
ity. Two 4-mm punch-biopsy specimens of the skin were obtained
from the upper thigh of each tenascin-X–deficient person for cul-
ture of dermal fibroblasts and immunohistochemical studies.
 
Enzyme-Linked Immunosorbent Assay, 
Immunohistochemical Analysis, and Western Blotting
 
Tenascin-X was detected with a rabbit polyclonal antiserum
 
23,26
 
and a new guinea pig antiserum, both raised against a 100-kD car-
boxy-terminal fragment of human tenascin-X expressed in 
 
Escher-
ichia coli
 
. Tenascin-C was detected with mouse monoclonal anti-
body T2H5
 
27
 
 and A107 rabbit polyclonal antiserum (Telios, La
Jolla, Calif.). No cross-reactivity between tenascin-X and tenascin-C
was found. Tenascin-C in serum was measured by enzyme-linked
immunosorbent assay (ELISA) according to the method described
by Latijnhouwers et al.,
 
28
 
 with a lower limit of detection of 5 ng per
milliliter. Tenascin-X was measured with use of a sandwich ELISA
with affinity-purified rabbit anti–tenascin-X for antigen capture. De-
tection of tenascin-X was performed with use of guinea pig anti–
tenascin-X, followed sequentially by biotinylated goat anti–guinea
pig immunoglobulin and peroxidase-conjugated avidin–biotin com-
plex (Vector Laboratories, Burlingame, Calif.). The lower limit of
detection of the ELISA for tenascin-X was 100 pg per milliliter.
A semiquantitative ELISA was first used to screen patients with
the Ehlers–Danlos syndrome, normal subjects, and patients with
psoriasis or rheumatoid arthritis in a single (1:50) dilution of se-
rum. For the quantitative determination of tenascin-X (Table 1), we
tested serial dilutions of serum. Patients with Ehlers–Danlos syn-
drome and control populations were compared by analysis of vari-
ance with post hoc testing by Duncan’s multiple-range test.
We immunostained cryosections of skin-biopsy specimens for
tenascin-X and tenascin-C using the antiserums described above.
Paraffin sections were stained with hematoxylin and eosin or an an-
tiserum to collagen V (Dako, Carpinteria, Calif.). Secondary anti-
serums (biotinylated antirabbit or anti–guinea pig immunoglobu-
lin) were followed by peroxidase-conjugated avidin–biotin complex
and aminoethylcarbazol as the chromogenic substrate (Vector Lab-
oratories). Western blotting of serum and fibroblast-culture su-
pernatant was performed as described previously.
 
23
 
Cell Culture
 
First to third passages of human skin fibroblasts were used. Cells
were grown in Dulbecco’s modified Eagle H21 medium (GIBCO
BRL, Rockville, Md.), supplemented with 10 percent fetal-calf se-
rum, 
 
L
 
-ascorbic acid (20 µg per milliliter), penicillin, and strep-
tomycin. Conditioned medium was harvested from confluent cul-
tures for assay of tenascin-X by ELISA and Western blotting.
 
Mutation Detection
 
Genomic DNA was prepared from peripheral blood or fibro-
blasts, and polymerase-chain-reaction (PCR) detection of the 30-kb
tenascin-X deletion was carried out as previously described.
 
23
 
 The
coding sequence of tenascin-X was PCR-amplified with 23 primer
pairs, with annealing at 62°C and extension for 2.5 minutes at
72°C for 35 cycles. The 12.5-kb region coding for tenascin-X was
sequenced directly from PCR products with use of 42 primers.
The sequences of primers used for PCR and DNA sequencing
and the sizes of amplified products are available as Supplemen-
tary Appendix 1 with the full text of this article at http://www.
nejm.org.
 
RESULTS
 
Absence of Tenascin-X in Serum from Patients 
with the Ehlers–Danlos Syndrome
 
Tenascin-X is normally secreted by skin fibroblasts
as a 450-kD protein that can be detected with anti-
bodies directed against its carboxy terminal (Fig. 1).
Because tenascin-C is found in serum, we tested nor-
 
*Serum levels of tenascin-X and tenascin-C were determined by enzyme-
linked immunosorbent assay. Tenascin-C levels in normal subjects and patients
with psoriasis are from Latijnhouwers et al.
 
28
 
 Tenascin-X and tenascin-C
levels were read from standard curves by using recombinant C-terminal ten-
ascin-X and purified tenascin-C. The indicated tenascin-X concentrations
should be interpreted as equivalent to recombinant tenascin-X, because nei-
ther the serum form nor full-length native tenascin-X is available for use as
a standard. Plus–minus values are means ±SD.
†P<0.001 for the comparison with the normal subjects.
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 T
 
ENASCIN
 
-C.*
 
S
 
UBJECTS
 
T
 
ENASCIN
 
-X T
 
ENASCIN
 
-C
 
NO
 
.
 
TESTED
 
ng/ml
 
NO
 
.
 
TESTED
 
µg/ml
Normal subjects 21 476±117 7 1.1±0.4
Patients with psoriasis 20 470±95 34 1.3±0.8
Patients with classic 
Ehlers–Danlos syndrome
31 448±217 31 1.2±0.5
Patient 1 <0.1 2.1
Patient 2 <0.1 1.1
Patient 3 <0.1 1.8
Patient 4 <0.1 1.1
Patient 5 <0.1 2.0
Obligate heterozygotes 12 217±57† Not 
determined
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mal human serum for the presence of tenascin-X.
Tenascin-X is also readily detected in normal serum,
but the serum form of tenascin-X is a 140-kD pro-
tein probably resulting from proteolytic cleavage or
alternative splicing of tenascin-X (Fig. 1). To confirm
that the immunoreactive species in serum is derived
from the tenascin-X gene, we verified that the serum
of the tenascin-X–deficient index patient
 
23
 
 also lacked
tenascin-X (Fig. 1).
Tenascin-X was readily detected by ELISA in se-
rum from 21 healthy subjects and from 146 of 151
patients with the Ehlers–Danlos syndrome. However,
five unrelated patients with the Ehlers–Danlos syn-
drome (designated Patients 1, 2, 3, 4, and 5) lacked
tenascin-X. We also tested serum from 75 patients
with psoriasis and 93 patients with rheumatoid arthri-
tis to determine whether tenascin-X deficiency was a
nonspecific result of skin or joint disease. Tenascin-X
was present in the specimens from all these patients.
We repeated the ELISA at multiple dilutions of
serum, using samples from the five tenascin-X–defi-
cient patients, normal subjects, patients with classic
Ehlers–Danlos syndrome who were not deficient in
tenascin-X in the initial screening, and patients with
psoriasis (Table 1). The control groups had similar
serum concentrations of tenascin-X, but tenascin-X
was again undetectable in serum samples from the five
tenascin-X–deficient patients. Although tenascin-C is
coexpressed with tenascin-X in tissues affected by the
Ehlers–Danlos syndrome, all the patients had normal
serum tenascin-C levels (Table 1).
 
Tenascin-X Deficiency in Skin and Fibroblasts of Patients 
with the Ehlers–Danlos Syndrome
 
Tenascin-X was readily detected in conditioned me-
dium from cultures of normal skin fibroblasts by West-
ern blotting (Fig. 1) and ELISA, although the mean
(±SD) amount of tenascin-X found in conditioned
medium (0.54±0.06 ng per milliliter in 48-hour su-
pernatants of confluent cells) was substantially less
than in serum. As expected, Western blotting and
ELISA did not detect tenascin-X in medium condi-
tioned by fibroblasts of the five patients who lacked
tenascin-X in their serum, a result that confirmed that
these patients had tenascin-X deficiency.
Histologic examination of skin-biopsy specimens
from tenascin-X–deficient patients revealed no gross
morphologic abnormalities, although the collagen net-
work in the papillary dermis appeared less dense (Fig.
2E) than in specimens of normal skin (Fig. 2A). Im-
munostaining showed abundant expression of ten-
ascin-X throughout the dermis of normal skin (Fig.
2B), whereas tenascin-X was completely absent in
skin from patients who lacked tenascin-X in their se-
rum (Fig. 2F). Tenascin-C and type V collagen were
expressed normally in dermis of tenascin-X–deficient
persons (Fig. 2C, 2D, 2G, and 2H).
 
Clinical Findings in Tenascin-X Deficiency
 
All five tenascin-X–deficient patients and three clin-
ically affected tenascin-X–deficient siblings had hy-
perelastic skin and hypermobile joints (Table 2 and
Fig. 2I and 2J), fulfilling major diagnostic criteria for
classic Ehlers–Danlos syndrome. Minor diagnostic cri-
teria supporting the diagnosis of classic Ehlers–Dan-
los syndrome in the tenascin-X–deficient patients and
their siblings included easy bruising in all, velvety
skin in seven, joint pain in two, and multiple sublux-
ations in three. No delayed wound healing or atrophic
scars were noted. For this reason and because of the
absence of evidence of dominant inheritance, four of
the five patients were unclassified at the time of re-
ferral. Of the eight tenascin-X–deficient patients, only
Patient 3 had coexisting congenital adrenal hyper-
plasia.
None of the parents of the five patients with ten-
ascin-X deficiency were related, and none of the four
parents available for study (from the families of Pa-
tients 1, 2, and 3) had clinical signs of the Ehlers–
Danlos syndrome. The father of Patient 1 had mitral
insufficiency, and the father of Patient 2 had atrial
arrhythmias and had had a cerebrovascular accident.
These tenascin-X–deficient patients also had a range
of additional clinical findings not frequently associat-
 
Figure 1.
 
 Detection of Tenascin-X in Culture Medium and Serum.
The figure shows a Western blot of fibroblast-conditioned me-
dium and serum from a normal subject and from the tenascin-
X–deficient index patient. In medium conditioned by normal fi-
broblasts, the 450-kD tenascin-X monomer was detected,
whereas in serum only a 140-kD species was present. No im-
munoreactive material was identified in fibroblast medium or
serum from the tenascin-X–deficient patient.
CultureE
Medium
Serum
— 450
Normal
IndexE
patient kD kDNormal
IndexE
patient
— 140
— 250
— 148
— 83
— 51
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Figure 2.
 
 Histopathological Findings in Skin in Patients with Tenascin-X Deficiency.
Panels A, B, C, and D show normal control skin, and Panels E through J show the skin and joints of a patient with the Ehlers–Danlos
syndrome and tenascin-X deficiency. Hematoxylin and eosin staining revealed less dense eosinophilic staining in tenascin-X–
deficient skin (Panel E) than in normal skin (Panel A) of the papillary dermis. Immunostaining with antiserum against recombinant
tenascin-X showed strong staining of the papillary dermis and moderate staining of the deeper dermal layers in normal skin (Panel
B), but no staining for tenascin-X was seen in the extracellular matrix of tenascin-X–deficient skin (Panel F). Staining for tenascin-
C (Panels C and G) and type V collagen (Panels F and H) was similar in control and tenascin-X–deficient skin. (Magnification in
Panels A through H, ¬250.) Panels I and J show the skin hyperextensibility and joint hypermobility typical of tenascin-X–deficient
patients with the Ehlers–Danlos syndrome.
A B C D
E F G H
I J
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ed with the Ehlers–Danlos syndrome (Table 2). These
included congenital adrenal hyperplasia, spina bifida
occulta, mitral-valve prolapse, stroke, gastrointestinal
bleeding, and premature arteriosclerosis. Although
these conditions contributed substantially to the dis-
ability of this cohort of tenascin-X–deficient patients,
it is not yet clear whether these additional disorders
were related to tenascin-X deficiency or were unre-
lated coexisting conditions.
 
Genetics of Tenascin-X Deficiency
 
The complete absence of tenascin-X messenger
RNA and protein in our index patient suggested that
tenascin-X deficiency is recessive.
 
23
 
 The index patient’s
phenotypically normal parents and siblings each shared
one tenascin-X allele with him, providing further ev-
idence of a recessive pattern of inheritance. However,
only the index patient’s paternal tenascin-X allele car-
ried a gene deletion, and complete sequencing of the
tenascin-X gene failed to identify a second mutation.
The present study allowed us to reexamine whether
isolated tenascin-X deficiency is dominant or recessive
(Fig. 3). In three of the families we studied (those of
Patients 3, 4, and 5), the patient was the only affected
member and both parents were phenotypically nor-
mal, a situation consistent with recessive inheritance
or with the presence of new dominant mutations in
each patient. In the other two families (those of Pa-
tients 1 and 2), there were three clinically affected
siblings of patients, all of whom were tenascin-X–
deficient. The presence of two or more affected sib-
lings makes new mutation an unlikely mechanism of
disease in these families. Furthermore, clinical Ehlers–
Danlos syndrome and tenascin-X deficiency were con-
fined to members of one generation in all five fami-
lies, also evidence of recessive inheritance. Finally, we
measured serum tenascin-X levels in 12 parents and
children of tenascin-X–deficient patients, who would
be obligatory heterozygotes if tenascin-X deficiency
were recessive. The mean serum tenascin-X concen-
tration in these persons was approximately half that
in controls (Table 1), a result consistent with haplo-
insufficiency and strongly supporting the hypothesis
of recessive inheritance.
 
Mutation Detection
 
We tested the tenascin-X–deficient patients for the
30-kb deletion described in the index patient.
 
23
 
 This
deletion creates a fusion gene of tenascin-X and XA,
a partial duplicate of tenascin-X. The XA gene has
an internal deletion that truncates its open reading
frame, rendering XA and the fusion gene nonfunc-
tional. The fusion gene can be amplified independ-
ently of the normal tenascin-X gene by allele-specific
PCR (Fig. 4A). Patient 3 had the same contiguous-
gene syndrome as the index patient, but unlike the
index patient, she was homozygous for the deletion,
which explains both the presence of Ehlers–Danlos
syndrome and that of congenital adrenal hyperplasia
(Fig. 4B). Both her parents and two siblings were het-
erozygous for the deletion and were clinically nor-
mal, providing evidence of recessive inheritance in
this family.
We next sequenced the tenascin-X gene in the re-
 
*Skin hyperextensibility was scored on a three-point scale: 0 absent, 1 present, and 2 severe.
†Joint hypermobility was assessed by the Beighton scale
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; ND denotes not determined. A score of 5 or more indicates
hypermobility.
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VELVETY
SKIN OTHER SYMPTOMS
Patient 1 F/43 1 5 + ¡ + Joint pain, striae
Sister of Patient 1 F/53 2 4 + ¡ + Goiter
Patient 2 F/39 1 7 + ¡ + Multiple subluxations, IgA deficien-
cy, spina bifida occulta
Sister of Patient 2 F/44 2 8 + ¡ + Multiple subluxations, chronic ob-
structive pulmonary disease
Brother of Patient 2 M/43 1 7 + ¡ + Hypertension
Patient 3 F/32 2 9 + ¡ + Congenital adrenal hyperplasia, Su-
deck’s atrophy of the left arm
Patient 4 M/44 1 4 + ¡ + Mitral-valve insufficiency, multiple 
subluxations, stroke, gastrointes-
tinal bleeding
Patient 5 F/48 2 ND + ¡ ¡ Arrhythmia, cardiomyopathy, arteri-
osclerosis, amputation of the left 
leg
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Figure 3. Pedigrees of the Five Tenascin-X–Deficient Patients.
Patients identified in the initial screening are indicated by arrows. Solid symbols indicate persons with complete tenas-
cin-X deficiency. Circles indicate female family members, squares male family members, and symbols with a slash mark
deceased members. Three additional affected family members were identified in the families of Patients 1 and 2. Brack-
ets indicate adopted children in the family of Patient 2, and the triangle in the family of Patient 5 represents a stillborn
female child. NND denotes neonatal death.
Family of Patient 1
Patient 1
Family of Patient 2
Patient 2
NND
Family of Patient 3
Patient 3
Family of Patient 4
Family of Patient 5
Patient 5
Patient 4
Figure 4 (facing page). Mutation Analysis of the Tenascin-X Gene.
The upper figure in Panel A shows a genetic map of the tenascin-X locus. The locus is duplicated into A and B loci at the positions
shown by the vertical dotted line. C4A and C4B encode isoforms of the fourth component of serum complement; 21A is a pseudo-
gene, and 21B is the functional 21-hydroxylase gene; XA is a partial duplicate of tenascin-X (TNX).29 Unique polymerase-chain-
reaction (PCR) primers were designed that are specific for XA (•) and tenascin-X (♦). These primers were paired with a tenascin-
X sense primer (—). The 30-kb deletion removes 21B and creates a nonfunctional tenascin-X–XA fusion gene (lower figure in Panel
A).23 XA is a partial duplicate of tenascin-X and has an internal deletion (∆). Panel B shows PCR products from the normal and
deleted alleles for Patient 3 and her family. M indicates molecular-size markers. The wild-type allele was present in all family mem-
bers except the patient (left), whereas the deleted allele was amplified from all family members (right). The patient was homozy-
gous for the deletion (solid symbols), which produces combined Ehlers–Danlos syndrome and congenital adrenal hyperplasia,
whereas unaffected parents and siblings were heterozygous for the deletion (hatched symbols). Panel C shows mutation analysis
of Patient 1 and her daughter. The nucleotide and predicted amino-acid sequences at the 3' end of exon 8 are shown above the top
two electropheretograms of Panels C and D. The bottom electrophoretogram of Panel C shows the DNA sequence of both alleles.
A two-nucleotide deletion (underlined) was found in codon 1184. Patient 1 was homozygous for this mutation, and her unaffected
father and daughter were heterozygous. FNIII denotes fibronectin type III. In Panel D, sequence analysis of exon 3, encoding the
epidermal growth factor (EGF) repeat domain, demonstrates a homozygous insertion of guanosine and thymine in Patient 4, which
changes a glutamic acid residue to a stop codon (asterisk).
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maining patients to identify point mutations or small
insertions or deletions. In Patient 1, we found a ho-
mozygous 2-bp deletion in exon 8 that encoded the
fourth fibronectin type III repeat (Fig. 4C). This de-
letion alters the open reading frame, affecting amino
acids 1184 through 1230, after which a premature
stop codon is encountered (not shown). The clini-
cally normal father of this patient was heterozygous
for the deletion (Fig. 4C). We could not examine
the mother because she had died (Fig. 3), but we
found that one of her sisters carried the deletion. It
is therefore likely that the mother of Patient 1 also car-
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ried this mutation, which would be consistent with
recessive inheritance. Patient 5 was also homozygous
for this mutation, but her parents were unavailable
for study. 
Patient 4 carried a homozygous 2-bp insertion in
exon 3, encoding the epidermal growth factor–like re-
peats of tenascin-X (Fig. 4D). The insertion of gua-
nosine and thymine replaced the glutamic acid residue
at position 707 with a stop codon. Additional family
members were not available for study.
Patient 2 was heterozygous for the 30-kb deletion
and did not have congenital adrenal hyperplasia. We
were unable to identify a second tenascin-X mutation
in this patient, although we sequenced the entire ten-
ascin-X gene. This patient, like our index patient, may
have had a mutation in factors, not yet defined, that
regulate tenascin-X gene expression.
Finally, we wondered whether missense mutations
in tenascin-X could also cause classic Ehlers–Danlos
syndrome. To answer this question, we sequenced the
entire tenascin-X gene in 10 patients who had classic
Ehlers–Danlos syndrome and normal serum levels of
tenascin-X. In these patients, we identified 26 DNA
polymorphisms, 8 of which change an amino acid
(data not shown). However, all 8 polymorphisms were
identified in a cohort of 48 normal persons, demon-
strating that these polymorphisms do not by them-
selves cause disease.
DISCUSSION
This study defines a form of the Ehlers–Danlos
syndrome that is both clinically and genetically dis-
tinct from previously described types.2 All tenascin-
X–deficient patients fulfilled three criteria for the
Ehlers–Danlos syndrome: they had hyperelastic skin,
hypermobile joints, and fragile tissue, manifested as
easy bruising. Although the clinical findings of ten-
ascin-X deficiency are similar to those of the classic
type of Ehlers–Danlos syndrome, the tenascin-X–
deficient patients we studied lacked atrophic scars, a
major diagnostic criterion for the classic type. De-
layed wound healing is also found frequently in pa-
tients with classic Ehlers–Danlos syndrome. Delayed
wound healing was found in our index patient but
was not a prominent feature of the present cohort.
Whether delayed wound healing is a rare finding in
tenascin-X deficiency or is a consequence of the treat-
ment of congenital adrenal hyperplasia with gluco-
corticoids is not clear.
Tenascin-X deficiency is also distinguished from
classic Ehlers–Danlos syndrome by its mode of inher-
itance. Classic Ehlers–Danlos syndrome is an autoso-
mal dominant disorder. Tenascin-X deficiency is reces-
sive, as shown by the occurrence of Ehlers–Danlos
syndrome in only one generation in each family; the
complete absence of tenascin-X protein from the se-
rum, skin, and fibroblast-conditioned medium of af-
fected persons; the lack of a clinical phenotype in
parents and offspring with tenascin-X haploinsuffi-
ciency; and the identification of homozygous tenas-
cin-X mutations in four of the five tenascin-X–defi-
cient patients.
Although more study is needed to determine
whether other conditions are associated with tenas-
cin-X deficiency, the list of coexisting diseases in this
cohort with isolated tenascin-X deficiency is striking
(Table 2) and suggests that tenascin-X deficiency may
be a particularly debilitating form of the Ehlers–
Danlos syndrome. The diagnosis should be considered
in patients with the Ehlers–Danlos syndrome who do
not have atrophic scars and in those without affected
family members, or when the disease is confined to
one generation. The availability of a simple serum-
based test for tenascin-X deficiency should make ac-
curate diagnosis of this deficiency possible in popula-
tions with the Ehlers–Danlos syndrome and should
lead to more widespread recognition of this variant.
Despite a decade of intensive investigation, very
little is known about the functions of the tenas-
cins.15,25,30 Patients with isolated tenascin-X deficiency
provide evidence of an in vivo function of the ten-
ascins, though it is not yet clear how tenascin-X defi-
ciency leads to the Ehlers–Danlos syndrome. Several
mechanisms of action of tenascin-X are possible. Ten-
ascin-X may be an important structural component
of the affected connective tissues. The fibronectin
type III repeats of titin and tenascin-C may be ca-
pable of reversible unfolding and refolding and may
thus act as serial elastic elements.31 Tenascin-X ap-
pears to be associated with collagen fibrils,32,33 so ten-
ascin-X may act as an elastic element linking adjacent
collagen fibrils and limiting the deformability of col-
lagenous matrix.
Tenascin-X may also affect fibrillar collagen synthe-
sis or fibrillogenesis. Type V collagen expression ap-
pears to be normal in tenascin-X–deficient patients,
but the synthesis of other fibrillar collagens has not
been examined.
Finally, it is possible that tenascin-X regulates col-
lagen deposition. Although the structure of fibrils is
normal in tenascin-X–deficient patients, the density
of the collagenous matrix in the skin appears to be re-
duced (Fig. 2). During development, tenascin-X ex-
pression is maximal when the connective-tissue scaf-
folding for muscle, tendon, and ligament is being laid
down,18 suggesting that tenascin-X may influence the
tissue-specific forms that fibrillar collagens assume.34
The search for additional causes of the Ehlers–Danlos
syndrome should now extend beyond the collagens.
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